Dermatology

Guest: Joe K. Tung, MD, MBA

While cigarette smoking is known to be linked to psoriasis, it was unclear whether or not e-cigarette use also carries risk. To address this research gap, a recent study analyzed data from over 28,000 United States adults, and, after adjusting for potential confounding variables, found that there is a statistically significant association between e-cigarette use and psoriasis. Hear Dr. Joe Tung, a coauthor of the study, break down its design and results, as well as potential reasons for this connection. Dr. Tung is a board-certified dermatologist who currently serves as the Medical Director of UPMC Falk Dermatology, Director of the Clinical Trials Unit, and Associate Director of the Dermatology Residency Program.

Guest: Joe K. Tung, MD, MBA

For dermatologists, treating psoriasis patients who use e-cigarettes can be challenging, particularly because of a lack of education about its risks, mental health concerns, and impacts on treatment efficacy. That being said, there are ways to address these challenges to support patients and improve outcomes. Join Dr. Joe Tung, a board-certified dermatologist who currently serves as the Medical Director of UPMC Falk Dermatology, Director of the Clinical Trials Unit, and Associate Director of the Dermatology Residency Program, as he discusses these barriers and potential solutions.

Guest: Robert Gniadecki, MD

Biologic therapies have helped significantly improve outcomes and quality of life for patients with psoriasis. With several IL-17 and IL-23 inhibitors now available, choosing between biologics often depends on the dermatologist’s experience, the patient’s needs, and potential side effects. Hear Dr. Robert Gniadecki, a Professor of Dermatology and the Director of the Division of Dermatology at the University of Alberta, discuss these treatment options and best practices for therapeutic decision-making.

Guest: Audrey Bui, DO

Genetic insights are reshaping how we understand the development and comorbidities of psoriasis, as well as treatment response in patients. Hear Dr. Audrey Bui discuss how genetic variants influence risks for certain conditions, how they may predict response to therapies like methotrexate, ustekinumab, and IL-17 inhibitors, and how integrating genetic markers into clinical care can enable more targeted, effective psoriasis management. Dr. Bui is a recent graduate from Lake Erie College of Osteopathic Medicine and an intern at the University of Central Florida prior to starting her dermatology residency at Hackensack Meridian Health Palisades Medical Center.

Host: Jennifer Schoch, MD, FAAD

On-demand webcast of expert faculty presentation on improving outcomes for pediatric patients with atopic dermatitis, including strategies for implementing systemic therapies and using patient-reported/caregiver-reported outcomes to deliver person-centered care.

Host: Philip Mease, MD, MACR

Guest: Steven Feldman, MD, PhD

On-demand webcast of expert faculty presentation and case discussion on managing obesity care in patients with psoriasis or psoriatic arthritis for dermatology and rheumatology healthcare professionals.

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: John Koo, MD

As the array of novel therapies for plaque psoriasis expands, a strategy to navigate treatment options is to focus on the specific needs of different patient groups, like Medicare-aged patients. ILUMYA® (tildrakizumab-asmn) is the only biologic for plaque psoriasis guaranteed to be covered under the medical benefit of Medicare, with no prior authorization and zero cost as a likely possibility. Join Dr Charles Turck and Dr John Koo as they share insights on the efficacy, safety, and accessibility of ILUMYA in this patient population. Dr. Koo is a Professor of Dermatology at the University of California at San Francisco School of Medicine.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA

Guest: Joel M. Gelfand, MD, MSCE, FAAD

Guest: Michael S. Garshick, MD

Inflammatory skin diseases like psoriasis don’t just affect the skin—they can often reflect broader cardiovascular risks. Given the overlap between dermatology and cardiology, knowing how to spot warning signs early and what steps to take during routine visits is key to comprehensive care. Joining Dr. Mary Cheeley to discuss the connection between the skin and the heart are Drs. Joel Gelfand and Michael Garshick. Dr. Gelfand is a dermatologist at the University of Pennsylvania and the Director of the Psoriasis and Phototherapy Treatment Center and the Center for Clinical Sciences in Dermatology. Dr. Garshick is a cardiologist and the Director of the Cardio-Rheumatology Program at NYU Langone Health, as well as an Assistant Professor of Medicine and Dermatology at NYU Grossman School of Medicine.

Guest: James Del Rosso, DO, FAOCD

Host: Charles Turck, PharmD, BCPS, BCCCP

Explore the latest breakthroughs in dermatology care with Dr. James Del Rosso, who highlights newly approved and emerging therapies for severe alopecia area, actinic keratosis, and atopic dermatitis. Dr. Del Rosso is the Research Director at JDR Dermatology Research, an Adjunct Clinical Professor of Dermatology at Touro University Nevada, and a practicing dermatologist in Las Vegas. He also presented on this topic at the 2025 Fall Clinical Dermatology Conference for Physician Assistants and Nurse Practitioners.

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Joel M. Gelfand, MD, MSCE, FAAD

Guest: Valerie Harrison, PhD

Home-based narrowband UVB phototherapy may offer a more accessible and effective option for managing psoriasis, as shown by the results of a recent study. With benefits like improved adherence, lower costs, and greater accessibility, this approach offers a compelling alternative for patients managing chronic disease. Explore the implications of this research and how it could shape future clinical practice with Dr. Joel Gelfand and Valerie Harrison. Dr. Gelfand is the Director of the Psoriasis and Phototherapy Treatment Center and the Center for Clinical Sciences in Dermatology at the University of Pennsylvania, as well as the lead investigator of the LITE study. Valerie Harrison is a study participant and a member of the National Psoriasis Foundation’s Board of Directors.